- Home
- FFC vs DNTH Comparison
FFC vs DNTH Comparison
Compare FFC & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFC
- DNTH
- Stock Information
- Founded
- FFC 1983
- DNTH 2015
- Country
- FFC United States
- DNTH United States
- Employees
- FFC N/A
- DNTH N/A
- Industry
- FFC Trusts Except Educational Religious and Charitable
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- FFC Finance
- DNTH Health Care
- Exchange
- FFC Nasdaq
- DNTH Nasdaq
- Market Cap
- FFC 781.9M
- DNTH 724.8M
- IPO Year
- FFC N/A
- DNTH N/A
- Fundamental
- Price
- FFC $15.93
- DNTH $19.99
- Analyst Decision
- FFC
- DNTH Strong Buy
- Analyst Count
- FFC 0
- DNTH 8
- Target Price
- FFC N/A
- DNTH $54.33
- AVG Volume (30 Days)
- FFC 164.1K
- DNTH 375.2K
- Earning Date
- FFC 01-01-0001
- DNTH 03-11-2025
- Dividend Yield
- FFC 6.79%
- DNTH N/A
- EPS Growth
- FFC N/A
- DNTH N/A
- EPS
- FFC N/A
- DNTH N/A
- Revenue
- FFC N/A
- DNTH $6,235,000.00
- Revenue This Year
- FFC N/A
- DNTH N/A
- Revenue Next Year
- FFC N/A
- DNTH N/A
- P/E Ratio
- FFC N/A
- DNTH N/A
- Revenue Growth
- FFC N/A
- DNTH 120.63
- 52 Week Low
- FFC $11.90
- DNTH $17.50
- 52 Week High
- FFC $14.96
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- FFC 45.24
- DNTH 44.36
- Support Level
- FFC $16.03
- DNTH $17.50
- Resistance Level
- FFC $16.20
- DNTH $21.77
- Average True Range (ATR)
- FFC 0.15
- DNTH 1.70
- MACD
- FFC -0.01
- DNTH -0.18
- Stochastic Oscillator
- FFC 31.25
- DNTH 36.51
About FFC Flaherty & Crumrine Preferred and Income Securities Fund Incorporated
Flaherty & Crumrine Preferred and Income Securities Fund Incorporated is a diversified, closed-end management investment company. The fund's investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. It invests in a diversified portfolio of preferred securities.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.